Geode Capital Management LLC Has $399.36 Million Stake in West Pharmaceutical Services, Inc. $WST

Geode Capital Management LLC cut its holdings in West Pharmaceutical Services, Inc. (NYSE:WST) by 1.1% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,833,004 shares of the medical instruments supplier’s stock after selling 20,689 shares during the period. Geode Capital Management LLC owned approximately 2.55% of West Pharmaceutical Services worth $399,356,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Dynamic Technology Lab Private Ltd acquired a new position in shares of West Pharmaceutical Services during the first quarter worth approximately $329,000. Polar Asset Management Partners Inc. lifted its holdings in shares of West Pharmaceutical Services by 106.5% in the first quarter. Polar Asset Management Partners Inc. now owns 53,070 shares of the medical instruments supplier’s stock valued at $11,881,000 after purchasing an additional 27,370 shares in the last quarter. Sivik Global Healthcare LLC boosted its position in shares of West Pharmaceutical Services by 20.0% during the second quarter. Sivik Global Healthcare LLC now owns 15,000 shares of the medical instruments supplier’s stock valued at $3,282,000 after buying an additional 2,500 shares during the last quarter. First National Bank Sioux Falls grew its holdings in West Pharmaceutical Services by 121.4% during the second quarter. First National Bank Sioux Falls now owns 4,727 shares of the medical instruments supplier’s stock worth $1,034,000 after buying an additional 2,592 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. raised its position in West Pharmaceutical Services by 15.6% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 14,774 shares of the medical instruments supplier’s stock valued at $3,233,000 after buying an additional 1,990 shares during the last quarter. 93.90% of the stock is owned by institutional investors and hedge funds.

West Pharmaceutical Services Stock Down 2.1%

West Pharmaceutical Services stock opened at $260.99 on Friday. The firm has a 50 day moving average price of $268.72 and a 200-day moving average price of $241.76. The company has a quick ratio of 2.18, a current ratio of 2.87 and a debt-to-equity ratio of 0.07. West Pharmaceutical Services, Inc. has a twelve month low of $187.43 and a twelve month high of $348.90. The company has a market capitalization of $18.78 billion, a P/E ratio of 38.67, a P/E/G ratio of 4.09 and a beta of 1.08.

West Pharmaceutical Services (NYSE:WST) last posted its quarterly earnings data on Thursday, October 23rd. The medical instruments supplier reported $1.96 EPS for the quarter, beating the consensus estimate of $1.67 by $0.29. West Pharmaceutical Services had a return on equity of 18.16% and a net margin of 16.29%.The business had revenue of $804.60 million for the quarter, compared to the consensus estimate of $788.42 million. During the same quarter in the prior year, the business earned $1.85 earnings per share. West Pharmaceutical Services’s revenue for the quarter was up 7.7% on a year-over-year basis. West Pharmaceutical Services has set its FY 2025 guidance at 7.060-7.110 EPS. As a group, equities analysts predict that West Pharmaceutical Services, Inc. will post 6.62 EPS for the current year.

Analyst Ratings Changes

WST has been the subject of several recent analyst reports. UBS Group upped their target price on shares of West Pharmaceutical Services from $320.00 to $355.00 and gave the stock a “buy” rating in a research note on Friday, October 24th. TD Cowen assumed coverage on shares of West Pharmaceutical Services in a research report on Wednesday, October 29th. They issued a “buy” rating and a $350.00 price objective for the company. Barclays increased their price objective on shares of West Pharmaceutical Services from $275.00 to $325.00 and gave the company an “equal weight” rating in a research note on Monday, October 27th. Deutsche Bank Aktiengesellschaft set a $345.00 target price on West Pharmaceutical Services and gave the stock a “buy” rating in a research note on Friday, October 24th. Finally, Zacks Research downgraded West Pharmaceutical Services from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 23rd. Two investment analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $349.20.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.